|
Market Research Report
Mitsubishi Tanabe Pharma: Pipeline * Products * Performance * Potential
|
Mitsubishi Tanabe Pharma:
Pipeline * Products * Performance * Potential published by Espicom Business Intelligence in April, 2009. This report consists of Pages: 100 and the price starts from US $ 1040.
Abstract
Pharmaceutical company intelligence reports from Espicom provide a full review
of the company' s activities together with five-year sales forecasts for its
key products. The company' s financial performance is covered in-depth, from
its latest results to a complete analysis of its latest full fiscal year and
an outlook for the future. A section on company strategy covers mergers,
acquisitions and divestitures, key agreements, products and R&D. An overview
of key products and R&D is followed by a comprehensive review of the company' s
product portfolio and research and development pipeline by therapeutic area.
In addition, supplementary appendices provide more in-depth information on
financials, agreements and corporate events.
Table of Contents
- EXECUTIVE SUMMARY
- A detailed and comprehensive overview of current financial position,
company strategy, product and pipeline analysis.
- THERAPEUTIC AREA FOCUS
- Key product analysis and forecasting
- Cardiovascular & Respiratory
- Anplag (sarpogrelate)
- Herbesser (diltiazem)
- Tanatril (imidapril)
- Neurology
- Ceredist (taltireline)
- Radicut (edavarone)
- Immunology & Inflammation
- Remicade (infliximab)
- Talion (bepotastine besilate)
- Gastrointestinal & Metabolism
- Urso (ursodeoxycholic acid)
- OPERATIONAL DATA
- A wealth of background and detail
- A full 5-year financial performance assessment
- Key corporate events
- Key agreements
- Infrastructure
- Subsidiaries and joint ventures
|
